references
STRATEGY
DNDi’s portfolio progression (2015-2023)
Portfolio
Disease areas Current portfolio Paediatric HIV HAT Chagas Filariasis Leishmaniasis New diseases Hepatitis C Mycetoma AMR Potential diseases Activities transferred New diseases (illustrative) Malaria 2015 2016 2017 2018
Progress
2019 2020 2021 2022-2023
Full portfolio (multiple projects at different phases)
Development
Implementation
Disease strategy complete
Incubator
This is what led DNDi to include paediatric HIV into its portfolio in 2011. Even though there is a strong R&D effort to develop better HIV/ AIDS treatments for adults, very little research is done for HIV-positive children. Current treatment options are insufficient, as little investment has been made to ensure the safety and efficacy of antiretrovirals in treating children. They are neglected patients. We now tackle hepatitis C: Despite an abundant pipeline of potential new drugs, developing country research needs are largely unaddressed, and existing products are unaffordable. The therapeutic advances brought about by direct-acting antivirals are not reaching patients. In an exciting new project launched in April 2016, DNDi aims to foster a public
health approach to the disease, by facilitating the development of an affordable pan-genotypic treatment. DNDi will also change how it does things. Not every disease area will require the same amount of effort and investment. A range of different operating models can be used, from integration into DNDi’s R&D portfolio, to various levels of more time-limited support such as knowledge sharing, advocacy, building new resource platforms, or serving as an incubator for an idea that may ultimately be externalized. By allowing for more flexible and diversified operational models, DNDi can tailor the breadth and depth of its engagement to a specific global health R&D need as it arises without jeopardizing our focus or draining resources. Resistance to antibiotic
treatments, for example, emerged as a key unmet medical need in our landscape analysis, and was considered best addressed through an incubator model, with a dedicated team (see p. 9). The roadmap towards 2023 In our 13 years of existence, DNDi has developed, implemented, or delivered six new treatments, for malaria, sleeping sickness, Chagas, and leishmaniasis, and developed a pipeline of over 30 projects. By our 20th anniversary in 2023, our ambition is to have delivered 16 to 18 new treatments, including two to three new chemical entities. Reaching this ambitious objective relies on an estimated budget of EUR 650 million covering the 20 year period since the creation of DNDi until 2023,
DNDi Annual Report 2015 › 7
